Grant RadarWorldwide funding
Log inGet started
Back to Grants
Health Open for ApplicationsPAR-25-226

Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Require

National Institutes of Health opportunity PAR-25-226

Eligible Applicants
Organization Types
UniversitiesNGOsSMEsGovernment Agencies
Eligible Countries / Regions
United States
Keywords
National Institutes of HealthPAR-25-226Grants.gov
Related Grants
Health● Open
Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional)
Varies
11 Aug 2027(313d)
Health● Open
DoW Orthopaedic, Clinical Research Award
Varies
18 Nov 2026(47d)
Health● Open
Maximizing the Scientific Value of Data Generated by the Environmental influences on Child Health Outcomes (ECHO) Program: Dissertation Grant (R36 - Clinical Trial Not Allowed)
Varies
15 Oct 2026(13d)
Health● Open
Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional)
Varies
16 Nov 2026(45d)
Funding Amount
Varies
USD
Application Deadline
19 November 2026
48 days remaining
Opens: 22 Nov 2024
Apply Now
Programme Details
Programme Code
PAR-25-226